Harman S M
Kronos Longevity Institute, Phoenix, AZ 85016, USA.
Climacteric. 2005 Jun;8(2):124-35. doi: 10.1080/13697130500118001.
Despite nearly a half-century of research on aging and sex steroids in men, answers to key questions that would allow us to confidently assess risk:benefit ratios for androgen replacement in older men with the partial androgen deficiency of aging men (PADAM) syndrome remain uncertain. Although it is now reasonably clear that a significant percentage of otherwise healthy older men have decreases in testosterone and bioavailable testosterone to levels consistent with hypogonadism, the clinical implications of this change remain uncertain. Data suggest that low testosterone in older men is correlated to varying degrees with loss of lean body mass and muscle strength, and increased total and central body fat. Less certain, but suggestive, are data relating low testosterone levels to decreased bone density, loss of insulin sensitivity, and cognitive and affective deterioration, as well as reduced sexual function. Replacement of testosterone in older men has shown some positive effects on each of these variables, but findings have been inconsistent, perhaps because studies have employed different preparations and doses of androgens, treated for various durations, and defined their target populations in different ways. As important as beneficial effects is the potential for adverse effects, which may be greater in older men. Possible problems include sleep apnea, erythrocytosis, dyslipidemia with acceleration of atherosclerosis, and, of greatest concern, prostate cancer or hyperplasia. Studies to date have suggested that these outcomes are not major risks, but, in the absence of a large, randomized trial or trials, definitive information is not available. The US National Academies Institute of Medicine's recent report recommends that the National Institutes of Health support small efficacy trials aimed at treatment of androgen deficiency-related clinical conditions, but not a large, randomized trial to elucidate risk:benefit ratios. This recommendation, if adhered to, is likely to delay, rather than foster, progress in this important area.
尽管针对男性衰老与性类固醇的研究已近半个世纪,但对于一些关键问题的答案仍不明确,这些问题能让我们有信心评估老年男性雄激素部分缺乏(PADAM)综合征患者雄激素替代疗法的风险效益比。虽然现在已经比较明确,相当一部分原本健康的老年男性睾酮及生物可利用睾酮水平下降至与性腺功能减退相符的程度,但这种变化的临床意义仍不明确。数据表明,老年男性睾酮水平低与瘦体重和肌肉力量的丧失以及总体和中心体脂肪增加在不同程度上相关。睾酮水平低与骨密度降低、胰岛素敏感性丧失、认知和情感衰退以及性功能减退之间的关系虽不太确定但有一定提示作用。老年男性补充睾酮已显示出对上述各项变量都有一些积极影响,但研究结果并不一致,这可能是因为研究采用了不同的雄激素制剂和剂量,治疗时间各异,且对目标人群的定义方式不同。与有益效果同样重要的是不良反应的可能性,而这在老年男性中可能更大。可能出现的问题包括睡眠呼吸暂停、红细胞增多症、加速动脉粥样硬化的血脂异常,以及最令人担忧的前列腺癌或前列腺增生。迄今为止的研究表明这些结果并非主要风险,但由于缺乏大规模随机试验,确切信息尚不可得。美国国家科学院医学研究所最近的报告建议美国国立卫生研究院支持旨在治疗雄激素缺乏相关临床病症的小型疗效试验,但不支持旨在阐明风险效益比的大规模随机试验。如果遵循这一建议,很可能会延迟而非促进这一重要领域的进展。